The opening salvo in what promises to be one of the hottest debates in the new Congress was fired January 29 during a day-long hearing in the House Committee on Oversight and Reform—how to lower the price of prescription drugs. And it didn’t take long to make it clear that patents are right in the middle of the scrum. The role of patents was a prominent part of the House hearing. While cursory nods were made to the importance of encouraging innovation, the witnesses discussed how patent exclusivity, thickets, and evergreening drove up prices while promoting the greater use of Patent Trial and Appeal Board (PTAB) reviews against drug patents. The Committee was assured that curtailing patents wouldn’t harm innovation because the National Institutes of Health (NIH) is such an important funder of life science R&D.
The post Patents in the Crosshairs During House Drug Pricing Debate appeared first on IPWatchdog.com | Patents & Patent Law.
Business
- Quickly Modeling Patent Market Prices
- ITIF Report Recommends Enhanced U.S. Tax Incentives for R&D
- Special Interest Group Implores Congress to Extend CBM Program
- Don’t Focus on the Fight: When it Comes to Trade Secrets, it’s the Transaction that Counts
- Microsoft Supports Epic Games’ Complaint Against Apple for Anti-Competitive Practices
Recent Posts
- California Court’s Finding of Fair Use for Nicki Minaj Affirms Public Benefit of Artistic Experimentation
- Quickly Modeling Patent Market Prices
- ‘Lead Development’ in Compound Claim Challenges
- Other Barks & Bites for Friday, September 25: Anonymous Precedential Decision Nominations at the PTAB, CAFC Rules on IPR Prior Art Estoppel in District Court and DOJ Issues Section 230 Proposals
- UK Judge Upholds Refusal of DABUS Patents